Glaucoma Market Size in the 7MM was ~USD 4,100 Million in 2022, as per DelveInsight

DelveInsight's "Glaucoma Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology, and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Glaucoma Market Report

* According to DelveInsight's analysis, the total diagnosed prevalent cases of Glaucoma in 7MM were found to be 7,045,443 in 2022 and are estimated to rise with a significant CAGR throughout the forecast period (2023-2034).
* DelveInsight estimates that the diagnosed prevalent cases of glaucoma in EU4 and the UK are expected to reach 3,877,921 by 2034 from 3,008,662 cases in 2022 during the forecast period (2023-2034) at a CAGR of 2.1%.
* As per DelveInsight's analysis, 54% of females and 46% of males in the 7MM were diagnosed with glaucoma in 2022. These cases are anticipated to rise in the forecast period (2023-2034).
* The leading Glaucoma Companies working in the market include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Promising Glaucoma Pipeline Therapies in the various stages of development include NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
* April 2024:- New World Medical Inc.- A Prospective, Randomized, Multi-center Evaluation of the Safety and Effectiveness of the STREAMLINE Registered SURGICAL SYSTEM Compared to iStent Inject W Registered in Patients With Open-Angle Glaucoma.
* April 2024:- Aerie Pharmaceuticals- A Multicenter, Open-Label Rocklatan Registered (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension. The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

Discover which therapies are expected to grab the Glaucoma Market Share @ Glaucoma Market Outlook [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Overview

Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination. Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK) and carbonic anhydrase inhibitors; however, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

Glaucoma Epidemiology Segmentation in the 7MM

* Total Glaucoma Prevalence Cases
* Prevalent Cases of Glaucoma by severity
* Glaucoma Gender-specific Prevalence Cases
* Diagnosed Cases of Episodic and Chronic Glaucoma

Download the report to understand which factors are driving Glaucoma Epidemiology trends @ Glaucoma Epidemiological Insights [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Market Insights

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But, treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination.

Glaucoma Treatment Market Landscape

Management of the condition revolves around reducing intraocular pressure (IOP) through the use of current drug classes, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. Despite these treatments, some patients do not experience the desired improvement in their condition. They may still face optic nerve damage even when their IOP levels are within the normal range. In addition to pharmacological treatments, alternatives such as incisional surgery, laser surgery, and medications are also considered.

To know more about Glaucoma treatment guidelines, visit @ Glaucoma Treatment Market Landscape [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glaucoma Drugs Uptake

* NCX 470 is a novel NO-donating bimatoprost eye drop, which is a prostaglandin analog. The drug is currently being developed by Nicox Ophthalmics and is in Phase III of clinical development. It is being developed for the treatment of open-angle glaucoma or ocular hypertension in the US. NCX 470 is designed to release bimatoprost and NO following instillation into the eye.
* PDP-716 is a novel, once-a-day formulation of brimonidine developed using SPARC's TearAct technology for the treatment of glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine, one of the most commonly used treatments for glaucoma and ocular hypertension.
* STN-1012600 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, STN-1012600 is expected to give new therapeutic options for treating glaucoma.

Glaucoma Market Outlook

The report's outlook on the Glaucoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glaucoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glaucoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glaucoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Major Glaucoma Companies

Several Glaucoma Companies working in the market include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries , and others.

Learn more about the FDA-approved drugs for Glaucoma @ Drugs for Glaucoma Treatment [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glaucoma Market Research Report

* Coverage- 7MM
* Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
* Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
* Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Glaucoma Drugs in development @ Glaucoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise Glaucoma Market Overview at a Glance

4. Glaucoma Market Overview by Class

5. Methodology of Glaucoma Epidemiology and Market

6. Executive Summary of Glaucoma

7. Key Events

8. Disease Background and Overview of Glaucoma

9. Epidemiology and Patient Population

10. Patient Journey

11. Glaucoma Marketed Therapies

12. Glaucoma Emerging Therapies

13. Glaucoma Market Analysis

14. Key Opinion Leaders' Views

15. Glaucoma SWOT Analysis

16. Glaucoma Unmet needs

17. Glaucoma Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-market-size-in-the-7mm-was-usd-4100-million-in-2022-as-per-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.